Activating TREM2 to Rebalance Microglia for Neuroprotection in ALS
- VHB937 is a novel mAb that binds microglial TREM2, stabilizing membrane TREM2 and activating signaling.
- VHB937 demonstrates neuroprotective activity across multiple models of neurodegeneration and neuroinflammation.
- In healthy participants, VHB937 decreases CSF inflammatory biomarkers (Spp1, sCSF1R and Ccl3)
- Clinical development: Phase II: ALS fully enrolled (ASTRALS, NCT06643481); AD initiated in 2025 (NCT07094516).